{
  "id": "IF10494",
  "type": "CRS In Focus",
  "typeId": "IF",
  "number": "IF10494",
  "active": false,
  "source": "CRSReports.Congress.gov",
  "versions": [
    {
      "source": "CRSReports.Congress.gov",
      "sourceLink": "https://crsreports.congress.gov/product/details?prodcode=IF10494",
      "id": "IF10494_2_2016-10-31",
      "date": "2016-10-31",
      "retrieved": "2020-09-05T09:22:18.949149",
      "title": "Risk Evaluation and Mitigation Strategies (REMS) and Generic Drugs",
      "summary": null,
      "type": "CRS In Focus",
      "typeId": "IF",
      "active": false,
      "formats": [
        {
          "format": "PDF",
          "url": "https://crsreports.congress.gov/product/pdf/IF/IF10494/2",
          "sha1": "c26ef4d2a8241e01a887f8076710d20dbc3b8afb",
          "filename": "files/2016-10-31_IF10494_c26ef4d2a8241e01a887f8076710d20dbc3b8afb.pdf"
        },
        {
          "format": "HTML",
          "filename": "files/2016-10-31_IF10494_c26ef4d2a8241e01a887f8076710d20dbc3b8afb.html",
          "source": "pymupdf"
        }
      ],
      "source_dir": "crsreports.congress.gov"
    }
  ],
  "topics": [
    "Health Policy"
  ]
}